The company contributes the decrease to an exit from two of its non-strategic product lines as well as a negative impact from foreign currency.
However, the company increased sales in the combined spine sector by 6 percent to $78.7 million, driven by an 11 percent increase in implants and biologics revenue. Fourth quarter net sales of the company’s orthopedic sector were $37.5 million, a 5 percent increase over the prior year. The increase was stimulated by external fixation and deformity correction hardware platforms and the use of Trinity Evolution.
The sales in the sports medicine sector were $35.1 million, a 9 percent increase from the fourth quarter of last year.
Read the release on the 4Q FY 2010 financial report from Orthofix.
Read other coverage on Orthofix:
– Orthofix Signs Agreement With Novation for Cold Therapy Products
– Orthofix Promotes Robert S. Vaters to COO
– Orthofix Releases Spinal Deformity Correction Product
